Sep 12, 2016 • 7:05 am EDT Corbus Pharmaceuticals Announces Last Subject Enrolled in Phase 2 Study of Resunab for the Treatment of Cystic Fibrosis
Aug 15, 2016 • 7:30 am EDT Corbus Pharmaceuticals Reports 2016 Second Quarter Financial Results and Provides Business Update
Jul 6, 2016 • 7:30 am EDT Corbus Pharmaceuticals to Present at the Cantor Fitzgerald 2nd Annual Healthcare Conference on July 12, 2016
Jun 17, 2016 • 7:00 am EDT Corbus Pharmaceuticals to Present at the JMP Securities Life Sciences Conference on June 22, 2016
Jun 16, 2016 • 7:00 am EDT Corbus Pharmaceuticals Announces Last Patient Enrolled in Phase 2 Study of Resunab for Systemic Sclerosis
May 16, 2016 • 8:13 am EDT Corbus Pharmaceuticals Reports 2016 First Quarter Financial Results and Provides Business Update
Apr 12, 2016 • 7:30 am EDT Corbus Pharmaceuticals Receives FDA Approval for Open-Label Extension to Its Phase 2 Trial of Resunab for Systemic Sclerosis